United States Biotechnology & Medical Research

Oncternal Therapeutics Inc (ONCT)

Track

Ticker: ONCT Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Oncternal Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 14 Oct 2024
Value US$3,385,006.40 | Price 278.52 | Shares 52,283
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-10-15 2024-10-14 PrS Proposed sale
2.5
Yazji Salim

Officer

Officer
52,283
278.52
US$3,385,006 		52,283 278.52 US$3,385,006
2024-04-10 2024-04-08 B Purchase
1.8
Wills Robert James
Non-Executive Director
88,799 -38.0%
463.56
US$1,161,216 		88,799 -38.0% 463.56 US$1,161,216
2024-04-01 2024-03-28 B Purchase
1.8
Wills Robert James
Non-Executive Director
84,740 +30.8%
12.58
US$1,515,212 		84,740 +30.8% 12.58 US$1,515,212
2024-02-27 2024-02-23 S Sale
1.8
Wills Robert James
Non-Executive Director
980 -100.0%
9.04
US$8,859 		980 -100.0% 9.04 US$8,859
2024-02-27 2024-02-23 B Purchase
1.4
HALE DAVID F
Non-Executive Director
266 +0.9%
9.04
US$2,405 		266 +0.9% 9.04 US$2,405
2024-02-27 2024-02-23 B Purchase
1.4
HALE DAVID F
Non-Executive Director
714 +inf%
9.04
US$6,455 		714 +inf% 9.04 US$6,455
2023-06-14 2023-06-14 B Purchase
1.9
Kaufmann Gunnar F.

Chief Scientific Officer

Officer
3,000 +3.3%
0.36
US$1,079 		3,000 +3.3% 0.36 US$1,079
2023-06-14 2023-06-12 B Purchase
1.9
Kaufmann Gunnar F.

Chief Scientific Officer

Officer
25,000 +37.5%
0.35
US$8,745 		25,000 +37.5% 0.35 US$8,745
2023-04-17 2023-04-14 B Purchase
3.0
BREITMEYER JAMES B

Chief Executive Officer

Executive Director
2,250 +1.2%
0.29
US$652 		2,250 +1.2% 0.29 US$652
2023-04-17 2023-04-14 B Purchase
3.0
BREITMEYER JAMES B

Chief Executive Officer

Executive Director
47,750 +32.6%
0.30
US$14,277 		47,750 +32.6% 0.30 US$14,277
2023-04-14 2023-04-14 B Purchase
2.5
Yazji Salim

Chief Medical Officer

Officer
5,000 +3.1%
0.30
US$1,500 		5,000 +3.1% 0.30 US$1,500
2023-04-17 2023-04-13 B Purchase
3.0
BREITMEYER JAMES B

Chief Executive Officer

Executive Director
100,000 +214.9%
0.29
US$29,000 		100,000 +214.9% 0.29 US$29,000
2023-04-14 2023-04-13 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
30,000 +23.6%
0.30
US$8,961 		30,000 +23.6% 0.30 US$8,961
2023-04-14 2023-04-13 B Purchase
2.5
Yazji Salim

Chief Medical Officer

Officer
10,000 +6.7%
0.29
US$2,850 		10,000 +6.7% 0.29 US$2,850
2023-04-14 2023-04-13 B Purchase
2.3
Leavitt Chase C.

General Counsel/Secretary

Officer
10,000 +10.3%
0.29
US$2,900 		10,000 +10.3% 0.29 US$2,900
2023-04-14 2023-04-12 B Purchase
2.5
Yazji Salim

Chief Medical Officer

Officer
10,000 +7.2%
0.29
US$2,850 		10,000 +7.2% 0.29 US$2,850
2023-04-14 2023-04-12 B Purchase
2.3
Leavitt Chase C.

General Counsel/Secretary

Officer
15,000 +18.3%
0.29
US$4,350 		15,000 +18.3% 0.29 US$4,350
2022-03-28 2022-03-28 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
2,500 +2.9%
1.40
US$3,500 		2,500 +2.9% 1.40 US$3,500
2022-03-28 2022-03-25 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
2,136 +2.6%
1.49
US$3,182 		2,136 +2.6% 1.49 US$3,182
2022-03-28 2022-03-25 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
5 +0.0%
1.48
US$7 		5 +0.0% 1.48 US$7
2022-03-28 2022-03-25 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
356 +0.4%
1.45
US$516 		356 +0.4% 1.45 US$516
2022-03-28 2022-03-24 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
3 +0.0%
1.45
US$4 		3 +0.0% 1.45 US$4
2022-01-31 2022-01-28 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
2,500 +3.1%
1.65
US$4,125 		2,500 +3.1% 1.65 US$4,125
2022-01-31 2022-01-28 B Purchase
2.3
Leavitt Chase C.

General Counsel/Secretary

Officer
5,000 +12.5%
1.63
US$8,150 		5,000 +12.5% 1.63 US$8,150
2022-01-31 2022-01-27 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
5,000 +6.6%
1.70
US$8,500 		5,000 +6.6% 1.70 US$8,500
2022-01-31 2022-01-27 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
5,000 +7.1%
1.80
US$9,000 		5,000 +7.1% 1.80 US$9,000
2022-01-31 2022-01-27 B Purchase
3.0
BREITMEYER JAMES B

Chief Executive Officer

Executive Director
25,000 +116.0%
1.68
US$42,080 		25,000 +116.0% 1.68 US$42,080
2022-01-31 2022-01-27 B Purchase
2.3
Leavitt Chase C.

General Counsel/Secretary

Officer
8,500 +27.1%
1.78
US$15,130 		8,500 +27.1% 1.78 US$15,130
2022-01-31 2022-01-27 B Purchase
2.5
Yazji Salim

Chief Medical Officer

Officer
10,000 +17.5%
1.69
US$16,900 		10,000 +17.5% 1.69 US$16,900
2021-06-15 2021-06-11 B Purchase
2.3
Leavitt Chase C.

General Counsel/Secretary

Officer
1,500 +inf%
5.45
US$8,175 		1,500 +inf% 5.45 US$8,175
2020-09-02 2020-09-01 B Purchase
2.4
CARTER MICHAEL G
Non-Executive Director
71,429 +13789.4%
2.10
US$150,001 		71,429 +13789.4% 2.10 US$150,001
2020-07-23 2020-07-21 B Purchase
2.3
Shanghai Pharmaceutical (USA) Inc.
Large shareholder
1,049,317 +42.1%
2.38
US$2,499,998 		1,049,317 +42.1% 2.38 US$2,499,998
2020-07-23 2020-07-21 B Purchase
2.3
KISNER DANIEL L
Non-Executive Director
10,000 +inf%
2.38
US$23,825 		10,000 +inf% 2.38 US$23,825
2020-07-23 2020-07-21 B Purchase
2.3
AKER HAZEL M

Legal Counsel

Officer
41,972 +836.9%
2.38
US$99,998 		41,972 +836.9% 2.38 US$99,998
2020-05-22 2020-05-21 B Purchase
1.4
HALE DAVID F
Non-Executive Director
17,412
0.00
US$0 		17,412 0.00 US$0
2018-06-26 2018-06-26 B Purchase Wills Robert James

Executive Chairman

Executive Director
5,000 +3.8%
16.75
US$83,750 		5,000 +3.8% 16.75 US$83,750
2018-06-22 2018-06-20 S Sale DOGGRELL HENRY PATTON

VP, Chief Legal Officer
7,351 -14.4%
19.01
US$139,708 		7,351 -14.4% 19.01 US$139,708
2018-06-22 2018-06-20 S Sale Shackelford Jason T

Prin Fin. & Acct. Officer
9,279 -32.3%
19.01
US$176,350 		9,279 -32.3% 19.01 US$176,350
2018-01-09 2018-01-05 S Sale Shackelford Jason T

Prin Fin. & Acct. Officer

Officer
2,379 -7.6%
11.13
US$26,478 		2,379 -7.6% 11.13 US$26,478
2018-01-09 2018-01-05 S Sale
0.5
Shackelford Jason T

Prin Fin. & Acct. Officer

Officer
711 -2.2%
12.02
US$8,546 		711 -2.2% 12.02 US$8,546
2018-01-09 2018-01-05 S Sale DOGGRELL HENRY PATTON

VP, Chief Legal Officer

Officer
3,823 -7.0%
11.13
US$42,550 		3,823 -7.0% 11.13 US$42,550
2018-01-09 2018-01-05 S Sale DOGGRELL HENRY PATTON

VP, Chief Legal Officer

Officer
1,142 -2.0%
12.02
US$13,727 		1,142 -2.0% 12.02 US$13,727
2018-01-09 2018-01-05 S Sale HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
5,628 -4.3%
11.13
US$62,640 		5,628 -4.3% 11.13 US$62,640
2018-01-09 2018-01-05 S Sale HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
1,681 -1.3%
12.02
US$20,206 		1,681 -1.3% 12.02 US$20,206
2017-10-02 2017-09-29 B Purchase Pyramid Peak Foundation Large shareholder
565,291
0.00
US$0 		565,291 0.00 US$0
2017-02-28 2016-10-28 S Sale Young Diane C.

VP, Chief Medical Officer
500 -100.0%
7.70
US$3,850 		500 -100.0% 7.70 US$3,850
2016-10-17 2016-10-14 B Purchase Pyramid Peak Foundation Large shareholder
7,716,049 +25.3%
0.81
US$6,250,000 		7,716,049 +25.3% 0.81 US$6,250,000
2016-06-20 2016-06-16 B Purchase Wills Robert James

Executive Chairman

Executive Director
100,000 +9.1%
0.65
US$65,360 		100,000 +9.1% 0.65 US$65,360
2016-03-02 2016-03-01 B Purchase GLASS J KENNETH Non-Executive Director
44,000 +31.5%
0.60
US$26,400 		44,000 +31.5% 0.60 US$26,400
2016-01-26 2016-01-26 B Purchase HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
4,000 +0.3%
0.65
US$2,600 		4,000 +0.3% 0.65 US$2,600
2016-01-25 2016-01-25 B Purchase HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
12,813 +1.0%
0.63
US$8,067 		12,813 +1.0% 0.63 US$8,067
2016-01-19 2016-01-19 B Purchase HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
25,000 +2.1%
0.50
US$12,428 		25,000 +2.1% 0.50 US$12,428
2016-01-15 2016-01-15 B Purchase HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
22,100 +1.9%
0.49
US$10,889 		22,100 +1.9% 0.49 US$10,889
2016-01-15 2016-01-14 B Purchase HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
2,900 +0.2%
0.47
US$1,377 		2,900 +0.2% 0.47 US$1,377
2015-12-28 2015-12-24 B Purchase GLASS J KENNETH Non-Executive Director
100 +0.1%
0.79
US$79 		100 +0.1% 0.79 US$79
2015-12-23 2015-12-23 B Purchase GLASS J KENNETH Non-Executive Director
600 +0.4%
0.79
US$474 		600 +0.4% 0.79 US$474
2015-12-23 2015-12-22 B Purchase GLASS J KENNETH Non-Executive Director
1,307 +0.9%
0.78
US$1,019 		1,307 +0.9% 0.78 US$1,019
2015-12-21 2015-12-21 B Purchase GLASS J KENNETH Non-Executive Director
39,900 +40.8%
0.78
US$31,122 		39,900 +40.8% 0.78 US$31,122
2015-05-20 2015-05-19 B Purchase GLASS J KENNETH Non-Executive Director
24,500 +inf%
1.25
US$30,625 		24,500 +inf% 1.25 US$30,625
2015-05-14 2015-05-14 B Purchase Wills Robert James

Executive Chairman

Executive Director
36,440 +57.3%
0.98
US$35,711 		36,440 +57.3% 0.98 US$35,711
2015-05-14 2015-05-13 B Purchase Wills Robert James

Executive Chairman

Executive Director
9,700 +18.0%
0.88
US$8,536 		9,700 +18.0% 0.88 US$8,536
2015-05-13 2015-05-11 B Purchase Wills Robert James

Executive Chairman

Executive Director
3,860 +7.7%
0.80
US$3,088 		3,860 +7.7% 0.80 US$3,088
2015-05-11 2015-05-08 B Purchase DOGGRELL HENRY PATTON

VP, Chief Legal Officer

Officer
25,477 +inf%
0.80
US$20,382 		25,477 +inf% 0.80 US$20,382
2015-05-11 2015-05-08 B Purchase Wills Robert James

Executive Chairman

Executive Director
50,000 +inf%
0.80
US$40,000 		50,000 +inf% 0.80 US$40,000
2015-04-23 2015-04-22 B Purchase GLASS J KENNETH Non-Executive Director
10,000 +11.4%
0.72
US$7,200 		10,000 +11.4% 0.72 US$7,200
2015-04-22 2015-04-21 B Purchase GLASS J KENNETH Non-Executive Director
7,656 +9.5%
0.71
US$5,436 		7,656 +9.5% 0.71 US$5,436
2015-04-22 2015-04-20 B Purchase GLASS J KENNETH Non-Executive Director
3,952 +5.2%
0.72
US$2,845 		3,952 +5.2% 0.72 US$2,845
2015-04-15 2015-04-15 B Purchase GLASS J KENNETH Non-Executive Director
3,300 +4.5%
0.72
US$2,376 		3,300 +4.5% 0.72 US$2,376
2015-04-13 2015-04-10 B Purchase GLASS J KENNETH Non-Executive Director
16,400 +29.0%
0.67
US$10,988 		16,400 +29.0% 0.67 US$10,988
2014-09-23 2014-09-23 B Purchase HANOVER MARC STEVEN

Interim CEO, President and COO

Executive Director
5,000 +2.4%
0.75
US$3,750 		5,000 +2.4% 0.75 US$3,750
2014-09-17 2014-09-17 B Purchase HANOVER MARC STEVEN

Interim CEO, President and COO

Executive Director
10,000 +5.0%
0.74
US$7,432 		10,000 +5.0% 0.74 US$7,432
2014-08-21 2014-08-21 B Purchase HANOVER MARC STEVEN

Interim CEO, President and COO

Executive Director
10,000 +5.3%
1.00
US$10,000 		10,000 +5.3% 1.00 US$10,000
2014-08-21 2014-08-20 B Purchase HANOVER MARC STEVEN

Interim CEO, President and COO

Executive Director
10,000 +5.6%
1.00
US$10,000 		10,000 +5.6% 1.00 US$10,000
2014-08-19 2014-08-19 B Purchase HANOVER MARC STEVEN

Interim CEO, President and COO

Executive Director
8,348 +4.9%
1.01
US$8,448 		8,348 +4.9% 1.01 US$8,448
2014-08-19 2014-08-15 B Purchase HANOVER MARC STEVEN

Interim CEO, President and COO

Executive Director
1,652 +1.0%
1.00
US$1,652 		1,652 +1.0% 1.00 US$1,652
Explore more

More insider trading research around Oncternal Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America